Posted by Michael Wonder on 02 Dec 2025
Baxdrostat new drug application accepted under FDA priority review in the US for patients with hard to control hypertension
2 December 2025 - Submission based on positive BaxHTN Phase 3 trial results which demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with resistant or uncontrolled hypertension.
AstraZeneca’s new drug application for baxdrostat has been accepted for priority review by the US FDA in the US for the treatment of adult patients with uncontrolled or treatment resistant hypertension as an add-on to other antihypertensive medicines when these do not provide adequate lowering of blood pressure.
